Apricus Biosciences, Inc. (APRI) Granted FDA Clearance for Second OTC Anti-Itch Drug Containing NexACT Technology
Apricus Biosciences, Inc. was pleased to announce earlier today that its wholly owned subsidiary, NexMed USA, has received clearance from the U.S. Food and Drug Administration to market its second, over-the-counter anti-itch drug, Hydrocortisone-D(TM). "This is the second clearance by the FDA of a drug containing Apricus Bio's NexACT(R) drug delivery technology, and as such, enhances our strategy of building out our OTC products division and creating a new revenue-generating portfolio for the Company," commented Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio." Apricus Bio's newly cleared OTC product combines hydrocortisone with DDAIP, the main ingredient…